The average premium was nearly $8,500 for single coverage and nearly $24,000 for family coverage this year, according to a new study published in Health Affairs.
Premiums rose 7% for employer-sponsored health coverage in 2023 Read More »
The insurer is actively seeking ways to mitigate the financial impact of its star ratings drop, Elevance CEO Gail Boudreaux said during the insurer’s third-quarter earnings call.
Elevance could see $500M quality bonus revenue hit in 2025 from MA star ratings drop Read More »
The collaborators assessed the feasibility of recycling medical waste such as plastic syringes.
BD recycles 40,000 pounds of medical waste in circular economy pilot project Read More »
Traverse Biotech, Inc announced today that the National Cancer Institute (NCI) of the National Institutes of Health has awarded them a Small Business Innovation Research (SBIR) Phase 1 Grant to fund the development of a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC).
Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023.
Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced that the U.S. Food and Drug Administration (FDA) has approved QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. QLOSI is expected to be commercially available in the U.S. in the first half of 2024.
A lo largo de la historia, los fenómenos paranormales han intrigado a la humanidad. Desde la telequinesis y la clarividencia hasta la percepción extrasensorial (PES), estos conceptos desafían nuestra comprensión convencional del mundo. Adentrémonos en el mundo de l …
Explorando los fenómenos paranormales: ¿Realidad o ilusión? Read More »
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced the U.S. Food and Drug Administration granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington’s disease.
Sensorion is pleased to announce its participation, in-person, in the European Society of Gene & Cell Therapy conference, taking place on October 24-27, 2023, in Brussels, Belgium.
Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference Read More »
Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced the opening of its Early Adopter Programme for its SemaCyte® Microcarrier Platform.
Semarion Announces Early Adopter Programme for SemaCyte Microcarrier Platform Read More »
